Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation

Tatsunori Ishikawa, Nobuharu Fujii, Masahide Imada, Michinori Aoe, Yusuke Meguri, Tomoko Inomata, Hiromi Nakashima, Keiko Fujii, Shohei Yoshida, Hisakazu Nishimori, Ken-ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. Case Report Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. Discussion A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. Conclusion Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.

Original languageEnglish
Pages (from-to)514-520
Number of pages7
JournalCytotherapy
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Azacitidine
Wilms Tumor
Hematopoietic Stem Cell Transplantation
Neoplasm Antigens
Leukemia
Tissue Donors
Lymphocytes
T-Lymphocytes
Transplants
Phenotype
Myelodysplastic Syndromes
Peripheral Blood Stem Cell Transplantation
Salvage Therapy
Memory Disorders
Acute Myeloid Leukemia
Therapeutics
Recurrence
Messenger RNA

Keywords

  • azacitidine
  • donor lymphocyte infusion
  • memory phenotype
  • Wilms tumor antigen 1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. / Ishikawa, Tatsunori; Fujii, Nobuharu; Imada, Masahide; Aoe, Michinori; Meguri, Yusuke; Inomata, Tomoko; Nakashima, Hiromi; Fujii, Keiko; Yoshida, Shohei; Nishimori, Hisakazu; Matsuoka, Ken-ichi; Kondo, Eisei; Maeda, Yoshinobu; Tanimoto, Mitsune.

In: Cytotherapy, Vol. 19, No. 4, 01.04.2017, p. 514-520.

Research output: Contribution to journalArticle

@article{ec6be7ab9632467fa4cdaba26c63a10f,
title = "Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation",
abstract = "Background Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. Case Report Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. Discussion A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. Conclusion Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.",
keywords = "azacitidine, donor lymphocyte infusion, memory phenotype, Wilms tumor antigen 1",
author = "Tatsunori Ishikawa and Nobuharu Fujii and Masahide Imada and Michinori Aoe and Yusuke Meguri and Tomoko Inomata and Hiromi Nakashima and Keiko Fujii and Shohei Yoshida and Hisakazu Nishimori and Ken-ichi Matsuoka and Eisei Kondo and Yoshinobu Maeda and Mitsune Tanimoto",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jcyt.2016.12.007",
language = "English",
volume = "19",
pages = "514--520",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation

AU - Ishikawa, Tatsunori

AU - Fujii, Nobuharu

AU - Imada, Masahide

AU - Aoe, Michinori

AU - Meguri, Yusuke

AU - Inomata, Tomoko

AU - Nakashima, Hiromi

AU - Fujii, Keiko

AU - Yoshida, Shohei

AU - Nishimori, Hisakazu

AU - Matsuoka, Ken-ichi

AU - Kondo, Eisei

AU - Maeda, Yoshinobu

AU - Tanimoto, Mitsune

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. Case Report Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. Discussion A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. Conclusion Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.

AB - Background Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. Case Report Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. Discussion A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. Conclusion Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.

KW - azacitidine

KW - donor lymphocyte infusion

KW - memory phenotype

KW - Wilms tumor antigen 1

UR - http://www.scopus.com/inward/record.url?scp=85010918142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010918142&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2016.12.007

DO - 10.1016/j.jcyt.2016.12.007

M3 - Article

C2 - 28139337

AN - SCOPUS:85010918142

VL - 19

SP - 514

EP - 520

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 4

ER -